Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Hong Kong.
Press releases published on September 1, 2025
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line …
INFLO to Join 2025 K-Tourism Roadshow in Hong Kong, Accelerating Global Expansion as a K-Medical Beauty Platform.
Up to 49% discount benefits offered… Operating a B2C booth for local consumers with direct reservations for Korea’s plastic surgery and dermatology procedures. SEOUL, SOUTH KOREA, September 1, 2025 /EINPresswire.com/ -- INFLO, a specialized K-Medical …
Bone Marrow Failure Market Growth Accelerates with Advances in Cell and Gene Therapy | DelveInsight
New York, USA, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Bone Marrow Failure Market Growth Accelerates with Advances in Cell and Gene Therapy | DelveInsight The bone marrow failure market is witnessing steady growth driven by the increasing prevalence of aplastic …
Healthcare Champions Launch Public Education Campaign to Address New Mexico’s Medical Access Crisis
Santa Fe, NM, Sept. 01, 2025 (GLOBE NEWSWIRE) -- A new public education campaign has been launched by Patient-Led NM, founded by the New Mexico Medical Society, New Mexico Hospital Association, Sacramento Mountains Foundation, and the Greater Albuquerque …
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in diabetic macular edema (DME) to be presented …
Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been approved based on an objective response rate of 71% (N=75), as demonstrated in the Beamion-LUNG 1 clinical trial1 Zongertinib recently received Breakthrough …